StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) stock

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$29.54−1.08 (-3.53%)

Close on Nov 13, 2026Market cap $1.16BP/E –Yield –

Alto Neuroscience total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Alto Neuroscience's total debt was $13.48M at Sep 30, 2026. For fiscal 2025 it was $16.76M, up 63.4% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.76M+63.4%
FY2024Dec 31, 2024$10.25M+4.0%
FY2023Dec 31, 2023$9.86M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$13.48M-33.6%
Q2 FY2026Jun 30, 2026$16.19M-19.6%
Q1 FY2026Mar 31, 2026$16.02M-19.7%
Q4 FY2025Dec 31, 2025$16.76M+63.4%
Q3 FY2025Sep 30, 2025$20.31M+100.0%
Q2 FY2025Jun 30, 2025$20.12M+100.1%
Q1 FY2025Mar 31, 2025$19.94M+100.2%
Q4 FY2024Dec 31, 2024$10.25M+4.0%
Q3 FY2024Sep 30, 2024$10.16M–
Q2 FY2024Jun 30, 2024$10.06M–
Q1 FY2024Mar 31, 2024$9.96M–
Q4 FY2023Dec 31, 2023$9.86M–

More Alto Neuroscience figures

See a number that looks wrong?